Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Clinical trial NCT05116462 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05116462
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-15
- Primary completion
- 2026-09-30
- Enrollment
- 506
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.